The

Laboratory Report Winter 2011

A Publication of the Department of Pathology and Genomic Medicine

Methodist, The University of

Texas M.D. Anderson Cancer Cen-

ter, the Mayo Clinic, Harvard

Medical School, and the Memorial

Sloan-Kettering Cancer Center.

Lectures on April 28th will involve

various topics in diagnostic pul-

monary pathology, while those on

April 29th will cover the current

status and future directions of

lung cancer diagnosis and treat-

ment. Seating for the Houston

Lung Symposium will be limited,

registration is required, and ad-

vance registration is highly recom-

mended.

To register for the symposium or ob-

tain the speaker agenda, visit houston-

pathologists.org/upcomingevents.

2

3

4

5

Laboratory Outreach Grows with The Methodist Hospital Reference Laboratories

New Faculty Join Department

New Diagnostic Test Offerings

Sugar Land Laboratory Supports Breast Center Expansion

Trainee Spotlight

Dr. Adriana Rosato Leads Methi-cillin-Resistant Staphylococcus Aureus Research Effort

Dr. Bogdan Czerniak to Present Chair’s Lectureship

Dr. Wayne Chandler Leads Test Utilization Improvement Effort

Table of Contents

Dr. Michael Thrall is leading the De-

partment’s efforts to implement digital

pathology technology into specific clini-

cal services in 2012. This cutting-edge

technology will allow for more rapid di-

agnoses for our patients and will enhance

education programs.

Look for a complete article on digital

pathology at Methodist in the spring 2012

issue of The Laboratory Report!

The Laboratory Report—Issue Archives

Would you like to view past issues of The Laboratory Report? All 2011 issues can be

viewed by visiting our Department website at methodisthealth.com/TheLaboratoryReport.

T he Department of Pathol-

ogy and Genomic Medi-

cine is collaborating with

the Houston Society of Clinical

Pathologists (HSCP) to host a

major symposium at Methodist

in 2012. The Spring Symposium

of the HSCP and the Depart-

ment’s Seminar on Advances in

Lung Cancer will combine for a

two-day event on April 28th and

29th in The Methodist Hospital

Research Institute auditorium.

The event, the Houston Lung

Symposium, is the brainchild of

Dr. Philip Cagle, medical director of pul-

monary pathology for the Department

and editor-in-chief of Archives of Pathol-

ogy and Laboratory Medicine.

“This symposium will convene some of

the most accomplished pathologists,

Department and Houston Society of Clinical Pathologists to Host Major Symposium

Dr. Cagle in the Research Institute auditorium.

oncologists, and bioinformatics experts

from Houston and around the world,”

said Dr. Cagle. “This is an excellent op-

portunity for physicians, scientists, and

trainees at all levels.”

The symposium will feature 20 speak-

ers from institutions including

In Our Next Issue...

The

LABORATORY REPORT

2

Laboratory Outreach Grows with The Methodist Hospital Reference Laboratories

interface software. A website will be

launched in early 2012.

For more information on TMHRL,

please contact Phuong Nguyen at

713-441-3484 or ptnguyen@tmhs.org.

subscribing non-Methodist

hospitals, multi-specialty

provider groups, and aca-

demic and commercial re-

search groups.

“The Methodist reputa-

tion for excellence in patient

care is strong, our depart-

ment faculty members are

renowned in their specialty

and subspecialty fields, and

we have great facilities,”

said Phuong Nguyen, out-

reach specialist for TMHRL.

“While the program has

done well, it has the poten-

tial to be much bigger and better.” New

infrastructure for the program is in the

final stages of development, and a state-

of-the-art test ordering and results deliv-

ery system is being implemented with the

latest generation of operating system

T he Department of Pathology and

Genomic Medicine and The Meth-

odist Hospital are further devel-

oping and expanding their laboratory

outreach program with the formation of

The Methodist Hospital Reference Labo-

ratories (TMHRL). TMHRL will provide

expanded clinical testing for The Method-

ist Hospital patients, additional testing

volume for esoteric tests, and method

development and teaching opportunities

for residents and fellows.

“This is a tremendous opportunity for

the Department and the hospital,” said

Dr. Wayne Chandler, vice-chair of clinical

innovation for the Department. “In addi-

tion to helping our institution, our pro-

gram can provide a service that helps

other institutions and providers improve

their standard of care. It’s a win-win

situation.” TMHRL extends the Depart-

ment’s clinical services and expertise to

Dr. Chandler and Phuong Nguyen.

New Faculty Join Department

T he Department of Pathology and Genomic Medicine continues to grow. Two new physicians have recently joined our faculty:

Lauri B. Campagna, M.D.

Staff Pathologist, Methodist West Houston Hospital

Dr. Campagna joins the Department from The University of Texas Southwestern Medical Center in

Dallas, TX where she was an assistant professor of surgical pathology and cytopathology. She re-

ceived her medical degree in 1991 from the University of Colorado School of Medicine in Denver,

CO. She completed an anatomic and clinical pathology residency and a cytopathology fellowship at

Methodist and the Baylor College of Medicine in Houston, TX. Dr. Campagna will primarily provide

anatomic and clinical pathology services at Methodist West Houston Hospital.

For more information on Dr. Campagna, visit methodisthealth.com/Campagna.

Bisong Haupt, M.D.

Staff Pathologist, Methodist Sugar Land Hospital

Dr. Haupt is an alumna of the pathology training programs here at Methodist where she completed

both an anatomic and clinical pathology residency and a surgical pathology fellowship. She rejoins

the Department from St. Louis University in St. Louis, MO where she was an assistant professor of

pathology. Dr. Haupt received her medical degree in 1982 from the Southeast University School of

Medicine in Nanjing, China. She will primarily provide anatomic and clinical pathology services at

Methodist Sugar land Hospital.

For more information on Dr. Haupt, visit methodisthealth.com/Haupt.

The

LABORATORY REPORT

3

Triage TOX Drug Screen

The Triage TOX Drug Screen (Triage

Drugs of Abuse Panel) from Alere now

also tests for the presence of metham-

phetamines and methadone. The assay

has also changed from a visually inter-

preted chromogenic immunoassay to an

automated fluorescence immunoassay.

The panel is highly accurate and

screens for up to 10 distinct classes of

abused drugs (illicit and prescription)

with results obtained in approximately

15 minutes. The screen includes assays

for the presence of amphetamines,

methamphetamines, barbiturates, benzo-

diazepines, cocaine, methadone, opiates,

phencyclidine, tetrahydrocannabinol,

and tricyclic antidepressants.

This screen is especially useful in ob-

taining a differential diagnosis for emer-

gency medicine cases that may or may

not involve drug abuse as a primary

cause or contributing factor. It is recom-

mended that preliminary positive results

from the screen be confirmed with gas

chromatography-mass spectroscopy. At

Methodist, acetaminophen/paracetamol

is assessed using a quantitative serum

measurement assay run on the Vitros

Fusion platform.

For more information on the improved

Triage TOX Drug Screen, contact Dr.

Ping Wang at pwang@tmhs.org or Toni

Emmott at temmott@tmhs.org.

New Diagnostic Test Offerings:

Adenovirus Real-Time PCR Assay

The Molecular Diagnostics Laboratory

of The Methodist Hospital System has

implemented a new real-time PCR assay

to detect adenovirus. Adenoviruses are

DNA viruses that cause several infec-

tious manifestations, including gastroen-

teritis, pneumonia, conjunctivitis, and

skin rashes. Importantly, adenovirus

infection can lead to graft failure and life

threatening disseminated disease in

transplant patients.

Real-time PCR is a highly sensitive and

specific method to detect the presence of

DNA from pathogens in clinical speci-

mens. The adenovirus real-time PCR

assay is the latest in a series of new mo-

lecular tests instituted by the Molecular

Diagnostics Laboratory. This test, which

was previously performed at a reference

laboratory, was introduced in-house on

November 1. Performing the test at

Methodist will improve patient care by

increasing quality, decreasing costs, and

minimizing turnaround times.

For more information on this assay or

other tests offered by the TMHS Molecu-

lar Diagnostics Laboratory, please con-

tact Dr. Randall Olsen at 713-441-6802

(rjolsen@tmhs.org) or Brant Hilson at 713-

441-5725 (bhilson@tmhs.org).

BinaxNOW Malaria Test and Helico-

bacter pylori Stool Antigen Test

The Clinical Microbiology Laboratory

of The Methodist Hospital System will

be offering two new antigen detection

assays in December: the BinaxNOW ma-

laria test by Inverness Medical and the

Helicobacter pylori Stool Antigen (HpSA)

test by Meridian Biosciences, Inc.

The BinaxNOW malaria test is an im-

munochromatographic assay for the

qualitative detection of Plasmodium anti-

gens. It targets the histidine-rich protein

II (HRPII), which is a specific antigen

common to all four malaria species capa-

ble of causing human infection - P. falci-

parum, P. vivax, P. ovale, and P. malariae.

The BinaxNOW assay is to be used in

conjunction with a malaria peripheral

blood smear. Although the BinaxNOW

assay is less sensitive than the malaria

BreathTek C-13 Urea Breath Test

The Outpatient Laboratory in Smith

Tower (Room 523) now offers the

BreathTek C-13 urea breath test to aid in

the initial diagnosis and post-treatment

monitoring of active Helicobacter pylori

infection. H. pylori is a Gram-negative,

microaerophilic bacterium found in the

stomach which causes duodenal and

gastric ulcers, and has been linked to the

development of stomach cancer. Several

studies have reported that initial antim-

icrobial therapies can fail in as many as 1

in 4 patients, so post-treatment monitor-

ing is important.

The BreathTek test from Otsuka Amer-

ica Pharmaceuticals is an easy, conven-

ient non-invasive and non-radioactive

test and can be administered in about 15

minutes. Patients should fast for at least

one hour and refrain from using antim-

icrobials, proton pump inhibitors, or bis-

muth preparations for two weeks prior to

testing.

For more information on the BreathTek

C-13 urea breath test, please contact Dr.

Ping Wang at pwang@tmhs.org or Tammy

Lefevers at tlefevers@tmhs.org.

BinaxNOW cont.

smear, it can provide results in 15 min-

utes. The advantage of this assay is that

it allows for rapid identification and

quicker implementation of therapy.

The HpSA test is an enzyme immuno-

assay that detects Helicobacter pylori pro-

teins in human stool. This assay has

demonstrated higher sensitivity and

specificity than serology or the urea

breath test, and thus is an important op-

tion in the non-invasive diagnosis of H.

pylori.

For more information on the Binax-

NOW malaria test or the HpSA test,

please contact Dr. James Davis at 713-441

-2437 or Pat Cernoch at 713-441-0333.

MALDI-TOF Mass Spectrometry

The Bruker BioTyper is now being used

in the Microbiology Laboratory. This

new MALDI-TOF mass spectrometer

rapidly identifies bacteria based on their

MALDI-TOF cont.

unique protein fingerprints. Validation

studies for Gram-negative organisms

were completed in December. Additional

validations for identifying yeast and

Gram-positive bacteria are ongoing. Im-

plementation of this exciting new tech-

nology at The Methodist Hospital will

significantly improve patient care by

increasing sensitivity and reducing turn-

around times.

For more information on the BioTyper

MALDI-TOF mass spectrometer, please

contact Dr. James Davis at 713-441-2437

or Pat Cernoch at 713-441-0333.

The

LABORATORY REPORT

4

Dr. Adriana Rosato Leads Methicillin-Resistant Staphylococcus Aureus Research Effort

Sugar Land Laboratory Supports Breast Center Expansion

T he Breast Center at Method-

ist Sugar Land Hospital has

undergone a significant

expansion to meet the needs of the

growing Fort Bend County commu-

nity. The new facility is larger and

provides the full continuum of care

– from screening through treatment

and survivorship – all in one inte-

grated and multidisciplinary set-

ting.

“Tissue diagnosis is a critical part

of the multidisciplinary treatment

plan of breast cancer,” said Dr.

Seema Mullick, medical director of Labo-

ratory Services at Methodist Sugar Land

Hospital. “Our goal is to provide an

accurate and timely biopsy report to

facilitate the personalized care that

each of our patients receive here at

Methodist Sugar Land Hospital.”

Breast biopsies and related anat-

omic pathology volumes have risen

considerably since the Breast Center

moved to its new location in Febru-

ary. The laboratory is expected to

assess more than 800 breast biopsies

in 2012.

For more information on Methodist

Sugar Land Hospital, visit method-

isthealth.com/sugarland.

Dr. Mullick in the Sugar Land laboratory.

Trainee Spotlight:

Elizabeth B. McQuitty, M.D. PGY4 Resident

Elizabeth McQuitty, M.D.

D r. Elizabeth McQuitty, a PGY4 resident, received a first place award for her oral

abstract presentation, “CD8-positive CD30-positive lymphomatoid papulosis and

its differential diagnosis: a review of 20 cases”, at the 48th Annual Meeting of the

American Society of Dermatopathology (ASDP) in Seattle, WA. She is also developing a text

book with Dr. Jae Ro on evidenced-based approaches to cancer diagnosis.

Dr. McQuitty received her Master of Architecture degree from Rice University in 2002. She

then pursued a medical degree from the Baylor College of Medicine where she was a mem-

ber of the Alpha Omega Alpha Honor Medical Society. She graduated in 2008 and joined

the pathology residency program at Methodist that same year. Dr. McQuitty will complete a

fellowship in molecular genetic pathology at Methodist in 2012.

D r. Adriana Rosato, a research

scientist in the Center for Mo-

lecular and Translational Hu-

man Infectious Diseases Research, is

leading the Department’s efforts to inves-

tigate the pathogenesis of multidrug-

resistant bacteria. With a five-year R01

grant from the National Institute of Al-

lergy and Infectious Diseases, her re-

search aims to identify molecular genetic

causes of drug resistance in methicillin-

resistant Staphylococcus aureus (MRSA).

“MRSA strains with low-level antibiotic

resistance are a serious concern in hospi-

tal settings and, more recently, the com-

munity,” said Dr. Rosato. “Data from our

studies could identify new drug targets

for development of a novel class of anti-

biotics.”

Dr. Rosato is also investi-

gating the mechanistic bases

and molecular pathways in-

volved in resistance to dapto-

mycin, a new class of cyclic

lipopeptide antibiotic that is

effective against MRSA. Al-

though daptomycin-resistant

S. aureus infections are ex-

tremely rare, they pose a con-

siderable treatment challenge

when they occur as optimal

therapy remains undefined

and the infections commonly

appear in patients with com-

plicated preexisting, deep-

seated infections such as osteomyelitis,

septic arthritis, or endocarditis.

For more information on Dr. Rosato,

Dr. Rosato in the laboratory.

visit methodisthealth.com/Rosato.

The

LABORATORY REPORT

5

will present the Chair’s Lectureship at

the Methodist Department of Pathology

and Genomic Medicine Grand Rounds

on Tuesday, February 7, 2012. Dr. Czer-

niak, a renowned genitourinary pathol-

ogy expert, will speak on molecular pa-

thology as it relates to bladder cancer

development and detection.

“Understanding the molecular genetic

basis of bladder cancers has allowed us

to develop promising new non-invasive

tests that detect the cancers in their earli-

est stages,” said Dr. Czerniak. “Genomic

research will ultimately provide us with

the information we need to improve the

standard of care for this patient popula-

tion – and many others.”

Dr. Czerniak’s research focuses on

early events of carcinogenesis using hu-

man bladder cancer as a model disease.

His laboratory is credited with the devel-

opment of a strategy that combines

D r. Bogdan Czerniak, chairman

ad interim and deputy division

head for research in the Depart-

ment of Pathology at The University of

Texas M.D. Anderson Cancer Center,

whole-organ topographic histologic and

molecular mapping. This approach has

provided unique information on initiat-

ing cancer events and on the existence of

a novel class of genes, termed forerunner

genes, which contribute to early expan-

sion of intraurothelial neoplasia by their

loss of function.

The Department of Pathology and Ge-

nomic Medicine Grand Rounds program

was established in 2010 and is directed

by Dr. Geoffrey Land, medical director of

histocompatibility and transplant immu-

nology for the Department.

For more information on the Depart-

ment Grand Rounds or a list of speakers

with dates and topics, visit method-

isthealth.com/pathologygrandrounds or con-

tact Victoria Watson at vlwat-

son@tmhs.org.

Dr. Wayne Chandler Leads Test Utilization Improvement Effort

Dr. Bogdan Czerniak to Present Chair’s Lectureship

Bogdan Czerniak, M.D., Ph.D.

T est utilization management

programs aim to evaluate the

clinical and fiscal effects of

test ordering with the goal of im-

proving patient care, increasing effi-

ciency, and reducing costs. Dr.

Wayne Chandler, vice-chair for clini-

cal innovation in the Department, is

directing such an effort at Methodist.

“Laboratory testing should pro-

vide the necessary clinical informa-

tion to the physician and use labora-

tory services appropriately and effec-

tively,” said Dr. Chandler. “Advances in

medical research and testing technology

are continuously affecting evidence-

based guidelines for patient care. It is

imperative that Methodist continually

monitor these changes and manage test

utilization accordingly.”

Dr. Chandler and colleagues at the Uni-

versity of Washington and Johns Hop-

kins Hospitals have conducted several

studies on test utilization. Their 2009

study focused on ionized calcium testing

and their most recent study, published in

Blood Coagulation and Fibrinolysis, investi-

gated the overuse of coagulation test

panels. Dr. Chandler and colleagues

found that the common cycle of calcium

screening and supplementation in unse-

lected patients (patients without known

or suspected specific derangements

in calcium metabolism) had no posi-

tive effect on outcomes. They also

found that the automated total cal-

cium test was a clinically suitable

screening test to determine the need

for an ionized calcium test in this

patient population. Their most recent

study found that coagulation test

panels are significantly overused and

often not clinically indicated, and

that the prothrombin time test more

often diagnosed vitamin K deficiency

than bleeding risk. The latter study also

evaluated the most effective methods of

implementing change in clinical test utili-

zation. Implementation of new test utili-

zation practices at Methodist will begin

in 2012.

For more information on test utilization

management at Methodist, please contact

Dr. Wayne Chandler at wlchan-

dler@tmhs.org.

Dr. Chandler meets with Laboratory Technologists, Heather Hendrickson (left) and Pam McShane (right).

The

LABORATORY REPORT

Ahmed N, Salsman V, Kew Y, Shaffer D, Powell S, Zhang Y, Grossman R, Heslop H, Gottschalk S. Generation of polyclonal CMV-

specific T cells for the adoptive immunotherapy of glioblastoma. Journal of Immunotherapy. 2011, In Press.

Amukele TK, Baird GS, Chandler WL. Reducing the use of coagulation test panels. Blood Coagul Fibrinolysis. 2011 Sep 19 [Epub ahead

of print]

Bond WS, Wadhwa L, Perlaky L, Penland RL, Hurwitz MY, Hurwitz RL, Chèvez-Barrios P. Establishment and propagation of human

retinoblastoma tumors in immune deficient mice. J Vis Exp. 2011 Aug 4;(54).

Carroll RK, Beres SB, Sitkiewicz I, Peterson L, Matsunami RK, Engler DA, Flores AR, Sumby P, Musser JM. Evolution of diversity in

epidemics revealed by analysis of the human bacterial pathogen group A Streptococcus. Epidemics. 2011 Sep;3(3-4):159-70.

Deleo FR, Kennedy AD, Chen L, Bubeck Wardenburg J, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Mar-

tens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN. Molecular differentiation of historic phage-type 80/81 and

contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18091-6.

Dhar SU, Chintagumpala M, Noll C, Chévez-Barrios P, Paysse EA, Plon SE. Outcomes of integrating genetics in management of pa-

tients with retinoblastoma. Arch Ophthalmol. 2011 Nov;129(11):1428-34.

Feske ML, Medina M, Graviss EA, Lewis DE. IL-7 addition increases spot size and number as measured by T-SPOT.TB (®). Methods

Mol Biol. 2012;792:229-41.

Feske ML, Teeter LD, Musser JM, Graviss EA. Giving TB wheels: Public transportation as a risk factor for tuberculosis transmission.

Tuberculosis (Edinb). 2011 Nov 14. [Epub ahead of print]

Feske ML, Teeter LD, Musser JM, Graviss EA. Including the third dimension: A spatial analysis of TB cases in Houston Harris

County.Tuberculosis (Edinb). 2011 Nov 15. [Epub ahead of print]

Gao L, Li F, Thrall MJ, Yang Y, Xing J, Hammoudi AA, Zhao H, Massoud Y, Cagle PT, Fan Y, Wong KK, Wang Z, Wong ST. On-the-

spot lung cancer differential diagnosis by label-free, molecular vibrational imaging and knowledge-based classification. J Biomed Opt.

2011 Sep;16(9):096004.

Hawiger J, Musser JM. How to approach genome wars in sepsis? Crit Care. 2011 Dec 2;15(6):1007. [Epub ahead of print]

Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA 3rd. Distinct

single amino Acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS

Pathog. 2011 Oct;7(10):e1002311.

Kosarac O, Zhai QJ, Shen S, Takei H, Ro JY, Ayala AG. Minimal or no residual prostatic adenocarcinoma on radical prostatectomy: a

5-year experience with "vanishing carcinoma phenomenon". Arch Pathol Lab Med. 2011 Nov;135(11):1466-70.

Koshy JC, Goldberg JS, Wolfswinkel EM, Ge Y, Heller L. Breast cancer incidence in adolescent males undergoing subcutaneous mas-

tectomy for gynecomastia: is pathologic examination justified? A retrospective and literature review. Plast Reconstr Surg. 2011 Jan;127

(1):1-7.

Kum JB, Grignon DJ, Wang M, Zhou M, Montironi R, Shen SS, Zhang S, Lopez-Beltran A, Eble JN, Cheng L. Mixed epithelial and

stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation. Am J Surg

Pathol. 2011 Aug;35(8):1114-22.

Kwon GY, Ro JY. Micropapillary variant of urothelial carcinoma. Adv Urol. 2011;2011:217153.

Lee H, Choi SK, Ro JY. Overexpression of DJ-1 and HSP90α and loss of PTEN associated with invasive urothelial carcinoma of uri-

nary bladder: possible prognostic markers. Oncology Letters. 2011, In Press.

McCall B, Pierce M, Graviss EA, Richards-Kortum R, Tkaczyk T. Toward a low-cost compact array microscopy platform for detection

of tuberculosis. Tuberculosis (Edinb). 2011 Nov 10. [Epub ahead of print]

Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE. VraSR two-component regulatory system con-

tributes to mprF-mediated decreased susceptibility to daptomycin in-vivo-selected MRSA clinical strains. Antimicrob Agents Chemo-

ther. 2011 Oct 10. [Epub ahead of print]

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth W, Nugent E, Han LY, Landen CN, Nick

AM, Stone RL, Coffman KT, Bruckheimer E, Broaddus R, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of

EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2011 Jan 12;10(12):1306-14.

Continued page 7

6

RECENT PUBLICATIONS

The

LABORATORY REPORT

Ping Wang, Ph.D. Claudia P. Molina, M.D.

Seema Mullick, M.D.

Thu Ngo, M.D.

Steven Shen, M.D., Ph.D.

Paul Sumby, Ph.D.

The Laboratory Report is a publication

of The Methodist Hospital System

Department of Pathology and

Genomic Medicine.

Nakhleh RE, Myer JL, Allen TC, Deyoung BR, Fitzgibbons PL, Funkhouser WK, Mody DR, Lynn A, Fatheree LA, Smith AT, Lal A,

Silverman JF. Consensus Statement on Effective Communication of Urgent Diagnoses and Significant, Unexpected Diagnoses in Sur-

gical Pathology and Cytopathology From the College of American Pathologists and Association of Directors of Anatomic and Surgical

Pathology. Arch Pathol Lab Med. 2011 Oct 13. [Epub ahead of print]

Nguyen DTM, NQ Hung, LT Giang, NH Dung, NTN Lan, NN Lan, NTB Yen, ND Bang, DV Ngoc, LTT Trinh, RP Beasley, L-Y

Hwang, EA Graviss. 2011. Improving the Diagnosis of Pulmonary Tuberculosis in HIV-Infected Individuals in Ho Chi Minh City, Viet-

nam. Int J Tuberc Lung Dis. 2011 Nov;15(11):1528-35.

Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 Expression in Primary and Metastatic Müllerian Epithelial Tu-

mors: A Comprehensive Comparison. Am J Surg Pathol. 2011 Dec;35(12):1837-47.

Powell SZ. Changes in residency training: shaping the future pathology workforce. Critical Values. 2011, In Press.

Ragunathan A, Olar A, Vogel H, Powell S, Fuller GN, Cahill D, Parker J, Aldape K. Isocitrate dehydrogenase 1 (IDH1) R132H muta-

tion is not detected in angiocentric glioma. Annals of Diagnostic Pathology. 2011, In Press.

Ro JY. Are elastic stain and specialty sign out necessary to evaluate pleural invasion in lung cancers? Annals of Diagnostic Pathology.

2011, In Press.

Shea PR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, Serrano-Gonzalez M, Fittipaldi

N, Beres SB, Flores AR, Low DE, Willey BM, Musser JM. Group A Streptococcus emm Gene Types in Pharyngeal Isolates, Ontario,

Canada, 2002-2010. Emerg Infect Dis. 2011 Nov;17(11):2010-7.

Shelburne Iii SA, Olsen RJ, Makthal N, Brown NG, Sahasrabhojane P, Watkins EM, Palzkill T, Musser JM, Kumaraswami M. An

amino-terminal signal peptide of Vfr protein negatively influences RopB-dependent SpeB expression and attenuates virulence in

Streptococcus pyogenes. Mol Microbiol. 2011 Oct 31. [Epub ahead of print]

Shin SJ, Kim KR, Song DE, Ro JY, Kong KY, Lee SW, Nam JH. Recognition of parametrial invasion, an important landmark when

treating cervical cancer. Gynecol Oncol. 2011 Nov 18. [Epub ahead of print]

Sniecinski RM, Chandler WL. Review articles: activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg.

2011 Dec;113(6):1319-33.

Son DH, Ro JY, Kang MJ, Jang WY, Cho YM. Histology and distribution of prostatic tissue on prostatic urethral margins: evaluation

of radical prostatectomy specimens and implications on frozen section analysis. Ann Diagn Pathol. 2011 Nov 1. [Epub ahead of print]

Stancel GA, Coffey D, Alvarez K, Halks-Miller M, Lal A, Mody D, Koen T, Fairley T, Monzon FA. Identification of tissue of origin in

body fluid specimens using a gene expression microarray assay. Cancer Cytopathol. 2011 Jun 29. [Epub ahead of print]

Wang P. Statin dose in Asians: is pharmacogenetics relevant? Pharmacogenomics. 2011 Nov;12(11):1605-15.

Yang Y, Li F, Gao L, Wang Z, Thrall MJ, Shen SS, Wong KK, Wong ST. Differential diagnosis of breast cancer using quantitative,

label-free and molecular vibrational imaging. Biomed Opt Express. 2011 Aug 1;2(8):2160-74.

Zarrin-Khameh N, Haas EM, Ro J, Thrall MJ. Lipomatosis coli, a mimicker of familial polyposis. Ann Diagn Pathol. 2011 Nov 4. [Epub

ahead of print]

Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, Zieske AW, Iwakuma T, Kolls JK, Cui Y. Trp53 negatively regulates auto-

immunity via the STAT3-Th17 axis. FASEB J. 2011 Jul;25(7):2387-98.

Zhao N, Fogg JM, Zechiedrich L, Zu Y. Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate

gene expression in lymphoma cells. Gene Ther. 2011 Mar;18(3):220-4.

RECENT PUBLICATIONS continued

7

Editor-in-Chief

April A. Ewton, M.D.

The Laboratory Report

Editorial Committee

Hazel L. Awalt, M.D.

Christopher Leveque, M.D.

The Methodist Hospital

Clare Rose, M.B.A.

Manuel Hinojosa, M.H.A.

Editorial Coordinator

Philip Randall

Department Chair

James M. Musser, M.D., Ph.D.